Fundraising FoxLiliumtx
1 known investors
Find your way into Liliumtx
Sign up to see every warm intro you have to Liliumtx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Liliumtx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lilium develops genetic medicines that selectively target pathogenic T cells in autoimmune diseases using engineered delivery vehicles for precision immune reprogramming. The company focuses on treating T-cell mediated autoimmune diseases and oncology indications that currently lack effective treatments.
Investors · 1
Related companies · 8
Luminary TherapeuticsLuminary Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies built on its Gamma 2.0+ platform to treat solid tumors, B-cell malignancies, and B-cell-mediated autoimmune diseases. The company uses a Dual CAR architecture and the TcBuster transposon system to address relapse, T cell exhaustion, and high manufacturing costs.
LyellLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
Lirum TherapeuticsLirum Therapeutics is a biopharmaceutical company that acquires, develops, and commercializes novel drug candidates for the treatment of difficult-to-treat, debilitating diseases. It was created by the former management team of Stemline Therapeutics.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Telo Therapeutics, Inc.Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
CalliotxCallio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
Valink TherapeuticsValink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as Liliumtx.
Frequently asked questions
- What does Liliumtx do?
- Lilium develops genetic medicines that selectively target pathogenic T cells in autoimmune diseases using engineered delivery vehicles for precision immune reprogramming. The company focuses on treating T-cell mediated autoimmune diseases and oncology indications that currently lack effective treatments.
- Who are Liliumtx's investors?
- Liliumtx's investors include Ulu Ventures.